A new nail in the CTCL coffin.
The impact of immunotherapy on the natural progression of cutaneous T-cell lymphoma (CTCL), particularly the mycosis fungoides and Sézary syndrome variants, has been based on our evolving understanding of the disease's immunobiology.
Lessin
Stuart R
SR
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. stuart.lessin@fccc.edu
D000818:Animals; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000628:therapy*; D051379:Mice; D009182:Mycosis Fungoides / Q000276:immunology / Q000628:therapy*; D012751:Sezary Syndrome / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*